Status:
UNKNOWN
''Efficacy of Propranolol in the Treatment of Infantile Hemangioma"
Lead Sponsor:
Assiut University
Conditions:
Infantile Hemangioma
Eligibility:
All Genders
1-1 years
Phase:
PHASE2
Brief Summary
''Evaluation of the Efficacy of Propranolol in the Treatment of Infantile Hemangioma"
Detailed Description
Infantile hemangiomas (IH) are benign tumors of vascular endothelium.They are the most common tumors of infancy. They occur in about 4% of infants, though early studies were as high as 10%, probably d...
Eligibility Criteria
Inclusion
- Children diagnosed with problematic infantile hemangiomas:
- A-Large hemangiomas at increased risk of scarring or disfigurement at any site. B-Hemangiomas carrying functional risks near the eyes, nose, natural orifices, limbs, genitalia.
- C-Ulcerated infantile hemangiomas. D-Uncomplicated progressive infantile hemangiomas with unpredictable future course.
- E-Life-threatening hemangiomas.
- Multiple hemangiomas
Exclusion
- Patients older than 1 year of age.
- Patients with heart diseases.
- Patients with history of bronchspasm or wheezing.
- Patients with Hypotension.
- Patients with Hypertension.
- Premature infants with corrected age less than 5 weeks.
- Patients with conditions affecting blood glucose maintenance.
- Patients with liver failure.
- Patients with PHACES syndrome.
Key Trial Info
Start Date :
January 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04684667
Start Date
January 1 2021
End Date
December 31 2021
Last Update
December 24 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assiut University Teaching Hospital
Asyut, Egypt, 71526